Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -8.00% is 75% above its 5-year average of -32.38%, near the high end of its 5-year range (-74.33%–-5.59%).
As of the fiscal period ended Tuesday, June 30, 2026. 60.40% above its 12-month average of -20.21%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -8.00%.
RETURN ON EQUITY (ROE)
-8.00%
RETURN ON EQUITY (ROE) AVG TTM
-20.21%
RETURN ON EQUITY (ROE) AVG 3Y
-25.43%
RETURN ON EQUITY (ROE) AVG 5Y
-32.38%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+60.40%
CURRENT VS 3Y AVG
+68.53%
CURRENT VS 5Y AVG
+75.28%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
11.44%
median of 92 covered companies
CURRENT VS SECTOR MEDIAN
-169.96%
vs the sector median at left
Beam Therapeutics Inc.
Market Cap
$2.51B
Return on Equity (ROE)
-8.00%
TTM Avg
-20.21%
3Y Avg
-25.43%
5Y Avg
-32.38%
Market Cap
$2.74B
Return on Equity (ROE)
29.28%
TTM Avg
27.86%
3Y Avg
4.54%
5Y Avg
-12.45%
Market Cap
$2.14B
Return on Equity (ROE)
-56.71%
TTM Avg
-50.91%
3Y Avg
-55.48%
5Y Avg
-35.68%
Market Cap
$1.73B
Return on Equity (ROE)
-40.41%
TTM Avg
-45.75%
3Y Avg
-30.11%
5Y Avg
-18.95%
Market Cap
$1.72B
Return on Equity (ROE)
-54.96%
TTM Avg
-60.50%
3Y Avg
-51.30%
5Y Avg
-42.73%
Market Cap
$1.00B
Return on Equity (ROE)
-13.54%
TTM Avg
-40.81%
3Y Avg
-170.75%
5Y Avg
-114.78%
Market Cap
$472.39M
Return on Equity (ROE)
-6.60%
TTM Avg
-10.82%
3Y Avg
-11.36%
5Y Avg
-7.59%
Market Cap
$459.30M
Return on Equity (ROE)
89.43%
TTM Avg
81.07%
3Y Avg
67.39%
5Y Avg
61.90%
Market Cap
$397.55M
Return on Equity (ROE)
-28.18%
TTM Avg
-0.06%
3Y Avg
10.58%
5Y Avg
10.58%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | $2.51B | -8.00% | -20.21% | -25.43% | -32.38% |
| TransMedics Group, Inc. (TMDX)vs › | $2.74B | 29.28% | 27.86% | 4.54% | -12.45% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.14B | -56.71% | -50.91% | -55.48% | -35.68% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.73B | -40.41% | -45.75% | -30.11% | -18.95% |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.72B | -54.96% | -60.50% | -51.30% | -42.73% |
| Teladoc Health, Inc. (TDOC)vs › | $1.00B | -13.54% | -40.81% | -170.75% | -114.78% |
| NeoGenomics, Inc. (NEO)vs › | $472.39M | -6.60% | -10.82% | -11.36% | -7.59% |
| NRC Health (NRC)vs › | $459.30M | 89.43% | 81.07% | 67.39% | 61.90% |
| Shoulder Innovations, Inc. (SI)vs › | $397.55M | -28.18% | -0.06% | 10.58% | 10.58% |
| PDS Biotechnology Corporation (PDSB)vs › | $41.03M | N/A | -285.38% | -206.98% | -151.57% |
ROE
-8.0%
ROA
-6.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -8.00% |
| 2026-03-31 | -5.59% |
| 2025-12-31 | -6.46% |
| 2025-09-30 | -42.92% |
| 2025-06-30 | -38.08% |
| 2025-03-31 | -34.49% |
| 2024-12-31 | -51.36% |
| 2024-09-30 | -18.15% |
| 2024-06-30 | -16.74% |
| 2024-03-31 | -14.75% |
| 2023-12-31 | -13.50% |
| 2023-09-30 | -40.27% |
| 2023-06-30 | -40.31% |
| 2023-03-31 | -41.54% |
| 2022-12-31 | -39.41% |
| 2022-09-30 | -44.15% |
| 2022-06-30 | -29.24% |
| 2022-03-31 | -28.74% |
| 2021-12-31 | -44.83% |
| 2021-09-30 | -47.01% |
| 2021-06-30 | -74.33% |
| 2021-03-31 | -86.57% |
| 2020-12-31 | -79.24% |
| 2020-09-30 | -63.47% |
| 2020-06-30 | -48.32% |
| 2020-03-31 | -36.41% |
| 2019-12-31 | -77.59% |
| 2019-09-30 | -59.71% |
| 2019-06-30 | -88.04% |
| 2019-03-31 | -88.59% |
| 2018-12-31 | -85.99% |
